• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A 28-year-old male with spontaneous coronary artery dissection complicated by apical thrombus and acute ischemic stroke: An interesting case
Radiol Case Rep. 2022 Nov 2;18(1):246-249. doi: 10.1016/j.radcr.2022.10.001. eCollection 2023 Jan.ABSTRACTSpontaneous coronary artery dissection is described as the intramural bleeding that separates the layers of an epicardial coronary artery wall, either with or without an intimal tear. Atherosclerosis, iatrogenic damage, or trauma are not linked to this syndrome. Here we present a 28-year-old male with 1 month history stroke but no any chronic disease as well family history of heart disease who presented with 2 days' duration of typical cardiac chest pain. Based on an emergency electrocardiogram that showed biphasic T-w...
Source: Atherosclerosis - November 10, 2022 Category: Cardiology Authors: Said Abdirahman Ahmed Mesut Karata ş L ütfi Öcal Mohamed Abdullahi Mohamud Ishak Ahmed Abdi Mohamed Omar Hassan Source Type: research

Abstract 132: The POWR Survey: Patient and Physician Perspectives on Outcomes Weighting in Revascularization. Session Title: Poster Session I
Conclusions: Patients and physicians agree on which outcomes are most (death and stroke)and least impactful (incision scar), but there is a lot of variability in between supporting the reporting of more adverse outcomes and not just those included in MACE.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Pandit, J. A., Gupta, V., Boyer, N., Ports, T. A., Yeghiazarians, Y., Boyle, A. J. Tags: Session Title: Poster Session I Source Type: research

Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry Coronary Heart Disease
Conclusions With prasugrel as an antiplatelet treatment option, contemporary practice shows low uptake of prasugrel and delays in P2Y12 antagonist initiation among NSTEMI patients. We also note concerning evidence of inappropriate use of prasugrel, and inadequate targeting of this more potent therapy to maximize the benefit/risk ratio.
Source: JAHA:Journal of the American Heart Association - April 14, 2014 Category: Cardiology Authors: Sherwood, M. W., Wiviott, S. D., Peng, S. A., Roe, M. T., DeLemos, J., Peterson, E. D., Wang, T. Y. Tags: Coronary Heart Disease Source Type: research